Moderna co-founder Robert Langer regains billionaire status after cancer vaccine success
Robert Langer's stake in Moderna jumped past the billion-dollar mark following a positive Phase 3 melanoma vaccine trial, restoring his billionaire rank.
A Phase 3 trial of an mRNA cancer vaccine developed by Moderna and Merck achieved its goals against melanoma, sending the biotech's stock up over 100 %. The surge lifted co-founder Robert Langer's roughly 3 % equity to an estimated $1.7 billion, re-entering him into the billionaire ranks per a Forbes analysis. Langer previously reached ten-figure wealth in November 2020 after Moderna's COVID-19 vaccine results and saw his net worth peak at $4.9 billion in 2021 before falling below the threshold.
His stake was valued around $730 million just days before the recent jump. The 77-year-old, dubbed the “Edison of Medicine,” has long championed career fulfillment over high salaries, urging young professionals to follow meaningful work. He recounted turning down 20 lucrative oil-industry offers early in his career to pursue scientific research. Fortune sought comment from Moderna but received none.
Why it matters
The story shows how breakthrough biotech trials can rapidly reshape personal fortunes and highlight the financial stakes of medical innovation.
How this story developed
- Aug 19 Moderna shares soar as experimental melanoma vaccine shows promising results
- Aug 19 Moderna’s stock surged after the trial data were released.
- Aug 20 Interim Phase 3 data indicated the vaccine satisfied the primary endpoint of recurrence‑free survival and a key secondary endpoint of distant metastasis‑free survival.
In this story
Related stories
3 in this thread